热稳定卡贝缩宫素与缩宫素预防阴道分娩后出血的比较
这项随机、双盲、非劣效性试验在10个国家23个中心纳入29,645名阴道分娩妇女,比较肌注热稳定卡贝缩宫素100 μg与缩宫素10 IU(均产后立即给药)预防产后出血的效果。主要终点之一(失血量≥500 ml或追加宫缩剂)发生率卡贝缩宫素组14.5% vs 缩宫素组14.4%(RR 1.01,95%CI 0.95–1.06),符合非劣效性;另一主要终点失血量≥1000 ml发生率1.51% vs 1.45%(RR 1.04,95%CI 0.87–1.25),置信区间跨过非劣效界值,未证实非劣效。两组追加宫缩剂、止血干预及不良事件无显著差异。
要点
- 阴道分娩后立即肌注热稳定卡贝缩宫素100 μg,在失血量≥500 ml或追加宫缩剂这一复合终点上不劣于缩宫素10 IU(14.5% vs 14.4%,RR 1.01,95%CI 0.95–1.06)。
- 失血量≥1000 ml终点:卡贝缩宫素组1.51% vs 缩宫素组1.45%(RR 1.04,95%CI 0.87–1.25),置信区间跨过非劣效界值1.23,非劣效性未证实。
- 该终点事件率低降低了试验把握度,是未证实非劣效的原因之一。
- 两组追加宫缩剂、止血干预及不良事件无显著差异。
- 两种药物在试验中均冷藏(2–8°C)以维持双盲,热稳定卡贝缩宫素的实际常温储存优势未在本文中直接验证。
适用人群与场景
- 10个国家23个中心纳入的阴道分娩妇女,产后立即给药。
处置流程与药物剂量
- 阴道分娩后立即肌内注射热稳定卡贝缩宫素100 μg,或缩宫素10 IU;试验中两种药物均冷藏于2–8°C以维持双盲。
研究设计与关键结果
- 随机、双盲、非劣效性试验,纳入29,645名阴道分娩妇女,比较肌注热稳定卡贝缩宫素100 μg与缩宫素10 IU。
- 主要终点1(失血量≥500 ml或追加宫缩剂):卡贝缩宫素组14.5% vs 缩宫素组14.4%,RR 1.01(95%CI 0.95–1.06),符合非劣效性(界值1.16)。
- 主要终点2(失血量≥1000 ml):卡贝缩宫素组1.51% vs 缩宫素组1.45%,RR 1.04(95%CI 0.87–1.25),置信区间跨过非劣效界值1.23,非劣效性未证实。
- 追加宫缩剂、止血干预及不良事件两组间无显著差异。
证据类型、等级与局限
- 证据类型:随机、双盲、非劣效性试验。
- 局限:失血量≥1000 ml终点事件率低,降低了试验把握度。
对床旁实践的改变
- 对于阴道分娩后预防产后出血,热稳定卡贝缩宫素100 μg肌注可作为缩宫素10 IU的替代选择之一,在失血量≥500 ml或追加宫缩剂方面不劣于缩宫素;但对失血量≥1000 ml的预防效果尚未证实非劣效。
- 试验中两种药物均冷藏保存,热稳定卡贝缩宫素在常温储存条件下的实际应用效果需结合原文未涉及的储存条件另行评估。
指南或共识出处
- CHAMPION试验,澳大利亚新西兰临床试验注册号ACTRN12614000870651;EudraCT号2014-004445-26;印度临床试验注册号CTRI/2016/05/006969。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Postpartum hemorrhage is the most common cause of maternal death. Oxytocin is the standard therapy for the prevention of postpartum hemorrhage, but it requires cold storage, which is not available in many countries. In a large trial, we compared a novel formulation of heat-stable carbetocin with oxytocin.
METHODS: We enrolled women across 23 sites in 10 countries in a randomized, double-blind, noninferiority trial comparing intramuscular injections of heat-stable carbetocin (at a dose of 100 μg) with oxytocin (at a dose of 10 IU) administered immediately after vaginal birth. Both drugs were kept in cold storage (2 to 8°C) to maintain double-blinding. There were two primary outcomes: the proportion of women with blood loss of at least 500 ml or the use of additional uterotonic agents, and the proportion of women with blood loss of at least 1000 ml. The noninferiority margins for the relative risks of these outcomes were 1.16 and 1.23, respectively.
RESULTS: A total of 29,645 women underwent randomization. The frequency of blood loss of at least 500 ml or the use of additional uterotonic agents was 14.5% in the carbetocin group and 14.4% in the oxytocin group (relative risk, 1.01; 95% confidence interval [CI], 0.95 to 1.06), a finding that was consistent with noninferiority. The frequency of blood loss of at least 1000 ml was 1.51% in the carbetocin group and 1.45% in the oxytocin group (relative risk, 1.04; 95% CI, 0.87 to 1.25), with the confidence interval crossing the margin of noninferiority. The use of additional uterotonic agents, interventions to stop bleeding, and adverse effects did not differ significantly between the two groups.
CONCLUSIONS: Heat-stable carbetocin was noninferior to oxytocin for the prevention of blood loss of at least 500 ml or the use of additional uterotonic agents. Noninferiority was not shown for the outcome of blood loss of at least 1000 ml; low event rates for this outcome reduced the power of the trial. (Funded by Merck Sharpe & Dohme; CHAMPION Australian New Zealand Clinical Trials Registry number, ACTRN12614000870651 ; EudraCT number, 2014-004445-26 ; and Clinical Trials Registry-India number, CTRI/2016/05/006969 .).
参考来源
- Widmer M, Piaggio G, Nguyen TMH, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med. 2018. PMID: 29949473. doi:10.1056/NEJMoa1805489
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。